Compare · BBC vs JHB
BBC vs JHB
Side-by-side comparison of Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Nuveen High Income November 2021 Target Term Fund (JHB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBC and JHB operate in n/a (n/a), so they compete in similar markets.
- JHB carries a market cap of $525.4M.
Virtus LifeSci Biotech Clinical Trials ETF
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Latest BBC
Latest JHB
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Termination and Liquidation
- SEC Form 25-NSE filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Liquidation Details
- SEC Form N-CSRS filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form N-PX filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form 3 filed by Lancellotta Amy B.R.
- Nuveen Corporate Income November 2021 Target Term Fund Announces Wind-Up Period
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund